Back to HZNP Stock Lookup
Pages: 1 2 3 »» Last Page

Horizon Therapeutics (HZNP) – Business Wire

Jul 16, 2021 08:30 AM Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
Jul 8, 2021 08:00 AM Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
Jul 1, 2021 11:43 AM NIRI Chicago Elects 2021-2022 Officers and Directors
Jun 30, 2021 08:00 AM Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
Jun 29, 2021 08:00 AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 28, 2021 09:00 AM Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jun 21, 2021 07:30 AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30 AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 18, 2021 12:30 PM Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Jun 17, 2021 07:00 AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 2, 2021 08:00 AM Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
May 27, 2021 08:00 AM Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
May 24, 2021 08:00 AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
May 21, 2021 08:00 AM Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology
May 20, 2021 08:30 AM Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®
May 13, 2021 11:30 AM Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company
May 6, 2021 04:30 PM Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
May 6, 2021 08:30 AM New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:00 AM Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
May 5, 2021 07:00 AM Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc
Apr 27, 2021 08:00 AM Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
Apr 20, 2021 04:04 AM Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Apr 16, 2021 08:30 AM New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 16, 2021 08:00 AM New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 12, 2021 08:30 AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Apr 8, 2021 08:00 AM Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
Apr 7, 2021 08:00 AM RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
Apr 5, 2021 08:30 AM New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
Mar 30, 2021 07:30 AM Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
Mar 29, 2021 10:05 AM Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership
Mar 25, 2021 08:00 AM First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
Mar 24, 2021 08:15 AM UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2021 08:00 AM Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
Mar 15, 2021 08:50 AM Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
Mar 12, 2021 08:45 AM Horizon Therapeutics plc Named Number One Best Workplace in Biopharma
Mar 11, 2021 03:00 AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Feb 26, 2021 04:05 PM Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
Feb 25, 2021 04:05 PM Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
Feb 24, 2021 07:00 AM Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
Feb 22, 2021 09:30 AM New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
Feb 4, 2021 01:00 AM Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 3, 2021 08:00 AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Feb 1, 2021 07:00 AM Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
Jan 11, 2021 07:00 AM Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New K
Dec 22, 2020 08:00 AM Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 17, 2020 06:40 AM Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production
Dec 3, 2020 09:00 AM Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education
Dec 2, 2020 09:15 AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Nov 30, 2020 08:00 AM Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities
Nov 25, 2020 08:00 AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Pages: 1 2 3 »» Last Page

Back to HZNP Stock Lookup